DK2219675T3 - Formuleringer for taci-immunglobulin-fusionsproteiner - Google Patents

Formuleringer for taci-immunglobulin-fusionsproteiner

Info

Publication number
DK2219675T3
DK2219675T3 DK08850454.3T DK08850454T DK2219675T3 DK 2219675 T3 DK2219675 T3 DK 2219675T3 DK 08850454 T DK08850454 T DK 08850454T DK 2219675 T3 DK2219675 T3 DK 2219675T3
Authority
DK
Denmark
Prior art keywords
taci
fusion protein
protein formulations
immunglobulin fusion
immunglobulin
Prior art date
Application number
DK08850454.3T
Other languages
English (en)
Inventor
Rio Alessandra Del
Gianluca Rinaldi
Joel Richard
Original Assignee
Ares Trading Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading Sa filed Critical Ares Trading Sa
Application granted granted Critical
Publication of DK2219675T3 publication Critical patent/DK2219675T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK08850454.3T 2007-11-12 2008-11-12 Formuleringer for taci-immunglobulin-fusionsproteiner DK2219675T3 (da)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP07120490 2007-11-12
EP07120489 2007-11-12
US302807P 2007-11-14 2007-11-14
US298807P 2007-11-14 2007-11-14
US7203808P 2008-03-27 2008-03-27
EP08005923 2008-03-27
PCT/EP2008/065395 WO2009062960A1 (en) 2007-11-12 2008-11-12 Formulations for taci-immunoglobulin fusion proteins

Publications (1)

Publication Number Publication Date
DK2219675T3 true DK2219675T3 (da) 2013-12-02

Family

ID=40347890

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08850454.3T DK2219675T3 (da) 2007-11-12 2008-11-12 Formuleringer for taci-immunglobulin-fusionsproteiner

Country Status (12)

Country Link
US (1) US8637021B2 (da)
EP (1) EP2219675B1 (da)
JP (1) JP5469077B2 (da)
CN (2) CN101854951A (da)
AU (1) AU2008322930B2 (da)
CA (1) CA2705357C (da)
DK (1) DK2219675T3 (da)
ES (1) ES2436779T3 (da)
IL (1) IL205716A (da)
PL (1) PL2219675T3 (da)
PT (1) PT2219675E (da)
WO (1) WO2009062960A1 (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0209933B8 (pt) 2001-05-24 2021-05-25 Zymogenetics Inc proteína de fusão, e, molécula de ácido nucleico
WO2007019573A2 (en) 2005-08-09 2007-02-15 Zymogenetics, Inc. Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules
CN101678106B (zh) 2007-03-27 2013-06-05 津莫吉尼蒂克斯公司 用于治疗自身免疫疾病的BLyS抑制和/或APRIL抑制与免疫抑制剂的组合
HUE030134T2 (en) 2007-10-16 2017-04-28 Zymogenetics Inc Combination of transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) and anti-CD20 agents for the treatment of autoimmune diseases
US8741591B2 (en) 2009-10-09 2014-06-03 The Research Foundation For The State University Of New York pH-insensitive glucose indicator protein
CN102085367B (zh) * 2011-01-19 2012-08-22 烟台荣昌生物工程有限公司 优化的TACI-Fc融合蛋白用于制备治疗类风湿性关节炎药物的应用
JP7749319B2 (ja) 2017-10-10 2025-10-06 アルパイン イミューン サイエンシズ インコーポレイテッド Ctla-4変異型免疫調節タンパク質およびそれらの使用
CN110522908A (zh) * 2018-05-25 2019-12-03 荣昌生物制药(烟台)有限公司 TACI-Fc融合蛋白用于制备治疗视神经脊髓炎谱系疾病和多发性硬化之药物中的应用
AU2020401160B2 (en) * 2019-12-10 2024-11-14 Remegen Co., Ltd. Pharmaceutical TACI-Fc fusion protein formulation
EP4146684A2 (en) 2020-05-08 2023-03-15 Alpine Immune Sciences, Inc. April and baff inhibitory immunomodulatory proteins with and without a t cell inhibitory protein and methods of use thereof
PH12022553243A1 (en) * 2020-06-02 2024-02-12 Ares Trading Sa Methods related to the treatment of iga nephropathy
US20240301031A1 (en) * 2021-03-31 2024-09-12 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Truncated taci polypeptide and fusion protein and use thereof
CN117529506A (zh) * 2021-06-11 2024-02-06 海南先声药业有限公司 抗人il-17抗体和taci的双功能融合蛋白分子
BR112023018745A2 (pt) * 2021-08-10 2024-03-12 Remegen Co Ltd Método para tratar nefropatia por iga com proteína de fusão de taci-fc
CN117916273A (zh) * 2021-09-30 2024-04-19 江苏恒瑞医药股份有限公司 抗il23抗体融合蛋白及用途
KR20240014066A (ko) * 2021-09-30 2024-01-31 레메젠 코, 리미티드 Taci-fc 융합 단백질을 사용하여 쇼그렌 증후군을 치료하는 방법
CN121152636A (zh) * 2023-07-06 2025-12-16 荣昌生物制药(烟台)股份有限公司 用TACI-Fc融合蛋白治疗ANCA相关性血管炎的方法
WO2026008004A1 (zh) * 2024-07-04 2026-01-08 荣昌生物制药(烟台)股份有限公司 用TACI-Fc融合蛋白治疗抗磷脂综合征的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
CA2635352C (en) * 1997-06-13 2012-09-11 Genentech, Inc. Stabilized antibody formulation
WO1999032135A1 (en) * 1997-12-22 1999-07-01 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
WO2001060397A1 (en) * 2000-02-16 2001-08-23 Genentech, Inc. Uses of agonists and antagonists to modulate activity of tnf-related molecules
US20060067933A1 (en) * 1999-01-07 2006-03-30 Gross Jane A Soluble receptor BR43x2 and methods of using
WO2001087977A2 (en) * 2000-05-12 2001-11-22 Amgen Inc. Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
AU2002213441B2 (en) * 2000-10-12 2006-10-26 Genentech, Inc. Reduced-viscosity concentrated protein formulations
BRPI0209933B8 (pt) 2001-05-24 2021-05-25 Zymogenetics Inc proteína de fusão, e, molécula de ácido nucleico
US20080267965A1 (en) * 2002-02-21 2008-10-30 Kalled Susan L Use of Bcma as an Immunoregulatory Agent
CN103520735B (zh) * 2004-12-22 2015-11-25 Ambrx公司 包含非天然编码的氨基酸的人生长激素配方
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
AU2006318583A1 (en) * 2005-11-22 2007-05-31 Wyeth Immunoglobulin fusion protein formulations

Also Published As

Publication number Publication date
PT2219675E (pt) 2013-11-18
CN105168123A (zh) 2015-12-23
EP2219675A1 (en) 2010-08-25
CN101854951A (zh) 2010-10-06
IL205716A (en) 2014-09-30
JP5469077B2 (ja) 2014-04-09
ES2436779T3 (es) 2014-01-07
US8637021B2 (en) 2014-01-28
IL205716A0 (en) 2010-11-30
AU2008322930B2 (en) 2014-05-15
CA2705357C (en) 2018-10-23
CN105168123B (zh) 2019-03-08
WO2009062960A1 (en) 2009-05-22
CA2705357A1 (en) 2009-05-22
EP2219675B1 (en) 2013-10-23
JP2011503038A (ja) 2011-01-27
AU2008322930A1 (en) 2009-05-22
US20100297122A1 (en) 2010-11-25
PL2219675T3 (pl) 2014-04-30

Similar Documents

Publication Publication Date Title
DK2219675T3 (da) Formuleringer for taci-immunglobulin-fusionsproteiner
FR2913672B1 (fr) Joint thermoscellable
PL2170388T3 (pl) Formulacje przeciwciał anty-CD20
BRPI0814252A2 (pt) Formulações de anticorpo
BRPI0820381A2 (pt) Formulações farmacêuticas
BRPI0908785A2 (pt) Formulações herbicida
EP2285310A4 (en) JOINT PROSTHESIS
DK2066354T3 (da) Norovirus vaccine formuleringer
DK3118220T3 (da) Protein
BRPI0814188A2 (pt) Formulações
EP2406388A4 (en) OX40 / TRAIL-FUSION PROTEIN
BRPI0814971A2 (pt) Proteína
EP2119738A4 (en) POLYETHYLENE GLYCOL DERIVATIVE
PT2144924T (pt) Vacina de proteína de fusão
CR10935A (es) Composicion fitosanitaria
PL2114142T3 (pl) Formulacje fitosanitarne
ES2569360T8 (es) Proteínas de fusión de ácaros
FR2913480B1 (fr) Joint tournant
EP2202422A4 (en) UNIVERSAL EQUIVALENT
DK2166996T3 (da) Kollapsibel stent
FR2897662B1 (fr) Joint homocinetique
FR2907178B1 (fr) Joint homocinetique
GB0700759D0 (en) Novel fusion protein
IS8612A (is) Stöðugar statínlyfjasamsetningar
GB0713169D0 (en) Fusion proteins